Faeth Therapeutics, Inc. filed a current report on Form 8-K on October 27, 2026, disclosing the appointment of Adam Schayowitz, Ph.D., as a Class III director effective October 23, 2026, following a Board expansion from six to seven members.

Key Highlights

  • Board expanded: The Board of Directors increased its size from six to seven directors on October 23, 2026.
  • New director: Adam Schayowitz, Ph.D. (age 46) was appointed as a Class III director, effective immediately upon the Board's action.
  • Term: Dr. Schayowitz will hold office until the Company's 2027 annual meeting of stockholders, or his earlier death, resignation, or removal.
  • Current role: Dr. Schayowitz has served as Executive Vice President and Head of Research and Development of Zymeworks Inc. (Nasdaq: ZYME) since April 2026.
  • Equity award: Dr. Schayowitz will receive an initial option to purchase 25,000 shares of common stock under the Company's 2026 Equity Incentive Plan, with an exercise price equal to the closing price on the date of grant.
  • Vesting schedule: The options vest in equal monthly installments through the third anniversary of the grant date, with full accelerated vesting upon a Change in Control, subject to continued service conditions.

Schayowitz Appointment Details and Background

According to the filing, Faeth Therapeutics' Board voted on October 23, 2026, to increase its size from six to seven directors and to appoint Adam Schayowitz, Ph.D., as a Class III director. The company is listed on NASDAQ:FTH. Dr. Schayowitz, age 46, will serve until the 2027 annual meeting of stockholders and until his successor is duly elected and qualified, or his earlier departure from the role.

The filing describes Dr. Schayowitz's professional background as spanning multiple biopharmaceutical organizations. He has held the role of Executive Vice President and Head of Research and Development at Zymeworks Inc. since April 2026, and previously served as its Acting Chief Development Officer from October 2025 to March 2026. Before that, he was an Operating Partner at EcoR1 Capital, LLC from September 2024 to March 2026. Prior to EcoR1, he held roles of increasing responsibility at Pfizer Oncology from January 2018 to September 2024, most recently as Vice President, Head of Product Development Teams, with development leadership across breast cancer, prostate cancer, colorectal cancer, and melanoma. Earlier positions included development work on Zejula (niraparib) at Tesaro, Inc. and Medical Affairs leadership at Algeta ASA supporting Xofigo (radium-223).

In connection with his appointment, the filing states Dr. Schayowitz will receive a cash retainer and an initial equity award consistent with the Company's non-employee director compensation program. The initial equity award is an option to purchase 25,000 shares under the 2026 Equity Incentive Plan, priced at the closing price of the Company's common stock on the grant date. The filing also notes that Dr. Schayowitz will enter into the Company's standard form of indemnification agreement for directors and executive officers. The filing confirms there are no family relationships between Dr. Schayowitz and any executive officers or directors, and no arrangements or understandings with any other person regarding his appointment.

What Was Disclosed

Faeth Therapeutics reported the expansion of its Board from six to seven members and the appointment of Adam Schayowitz, Ph.D., as Class III director effective October 23, 2026, along with details of his compensation, vesting terms, and professional background.